Fig. 3

FGF21 treatment alleviates VILI in mice. A. Hematoxylin–eosin staining of lung tissues and average lung injury scores analysis of lung slices (N = 5, scale bar = 500 μm in low-power images and = 50 μm in amplified images); B. TUNEL staining of lung tissues and dead cells counting of lung slices (N = 5, scale bar = 100 μm); C. H&E staining of exfoliated cells and total cell counting in BALF (N = 6, scale bar = 20 μm); D. Neutrophil count in BALF; E. The content of Evans blue dye in lung tissue; F. Protein concentration in BALF; G. Wet/dry ratio of lung tissue; H. MPO activity in lung tissue. I. Trolox-equivalent antioxidant capacity in mice lung tissue. J. ATP level in mice lung tissue; K. Timeline of the treating experiment. ns, no significance, ^*P < 0.05, ^**P < 0.01 vs. Control; ^#P < 0.05, ^##P < 0.01 vs. PBS; MV, mechanical ventilation; TUNEL, TdT-mediated dUTP nick end labeling; DAPI, 4',6-diamidino-2-phenylindole; BALF, bronchoalveolar lavage fluid; MPO, Myeloperoxidase; TEAC, Trolox-equivalent antioxidant capacity